KEVIN NGUYEN: Open Payments
NPI 1902420912 · POMONA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$756 in 33 payments from 21 companies in 2025. Trend: 2023 $140 · 2024 $143 · 2025 $756
Food & beverage: $756
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $66 |
| Merck Sharp & Dohme LLC | 3 | $66 |
| Madrigal Pharmaceuticals | 2 | $63 |
| Xeris Pharmaceuticals, Inc. | 3 | $51 |
| ViiV Healthcare Company | 2 | $50 |
| Janssen Pharmaceuticals, Inc | 2 | $47 |
| Astellas Pharma US Inc | 2 | $41 |
| SHIELD THERAPEUTICS INC | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Dexcom, Inc. | 2 | $36 |
Products named: REZDIFFRA, GVOKE HYPOPEN, CABENUVA, INVEGA SUSTENNA, Veozah, ACCRUFER, LIBTAYO, Dexcom G6 Transmitter.
Industry payments across CA — which companies pay providers there.
